It inhibits effector T cell activation in vivo and NK cytotoxicity by binding to CD115 and CD112 molecules on dendritic cells (DCs) and macrophages (TAMs/MФ), but also to ligands on the tumour cell surface, thus facilitating the mechanisms of immune escape in the cancer immune cycle [405,406,407,408]. This evidence concerns the gene CSF1R and neoplasm.